Dashboard
Financial statements
ZTS

Company financials

Zoetis

Health Care Pharmaceuticals Parsippany, New Jersey Last filing Feb 12, 2026 · FY2025
Revenue FY2025
$9.5B
Net income FY2025
$2.7B

Balance Sheet

Assets, liabilities, and equity

32 accounts · 5 years
Account 2025 2024 2023 2022 2021
Statement
BS Assets Cash $2.3B $2.0B $2.0B $3.6B $3.5B
BS Assets Accts Receivable $1.6B $1.3B $1.3B $1.2B $1.1B
BS Assets Inventory $2.4B $2.3B $2.6B $2.3B $1.9B
BS Assets Prepaid Expenses $436.0M $377.0M $434.0M $365.0M $389.0M
BS Assets Other Current Assets $436.0M $377.0M $434.0M $365.0M $389.0M
BS Assets Total Current $6.8B $6.0B $6.3B $7.5B $6.9B
BS Assets PPE $3.7B $3.4B $3.2B $2.8B $2.4B
BS Assets Op Lease ROU $288.0M $219.0M $230.0M $220.0M $181.0M
BS Assets Goodwill $2.8B $2.7B $2.8B $2.7B $2.7B
BS Assets Intangible Assets $998.0M $1.1B $1.3B $1.4B $1.5B
BS Assets Deferred Tax Assets $637.0M $540.0M $206.0M $173.0M $100.0M
BS Assets Other Noncurrent $328.0M $250.0M $206.0M $147.0M $111.0M
BS Assets Total $15.5B $14.2B $14.3B $14.9B $13.9B
BS Liab Accts Payable $487.0M $433.0M $411.0M $405.0M $436.0M
BS Liab Accrued Liab $642.0M $746.0M $683.0M $682.0M $710.0M
BS Liab Current Debt $0 $1.4B $0 $1.4B $0
BS Liab Other Current $107.0M $125.0M $102.0M $97.0M $67.0M
BS Liab Total Current $2.2B $3.4B $1.9B $3.2B $1.8B
BS Liab Long Term Debt $9.0B $5.2B $6.6B $6.6B $6.6B
BS Liab Op Lease Noncurrent $196.0M $174.0M $188.0M $186.0M $151.0M
BS Liab Deferred Tax Liab $139.0M $167.0M $146.0M $142.0M $320.0M
BS Liab Other Noncurrent $248.0M $222.0M $237.0M $217.0M $239.0M
BS Liab Total $12.1B $9.5B $9.3B $10.5B $9.4B
BS Equity Preferred Stock $0 $0 $0 $0 $0
BS Equity Common Stock $5.0M $5.0M $5.0M $5.0M $5.0M
BS Equity APIC $1.1B $1.2B $1.1B $1.1B $1.1B
BS Equity Retained Earnings $13.7B $12.0B $10.3B $8.7B $7.2B
BS Equity Treasury Stock $10.7B $7.4B $5.6B $4.5B $3.0B
BS Equity AOCI $-834.0M $-940.0M $-839.0M $-817.0M $-764.0M
BS Equity NCI $0 $0 $-6.0M $-2.0M $1.0M
BS Equity Total $3.3B $4.8B $5.0B $4.4B $4.5B
BS Equity Total Liab and Equity $15.5B $14.2B $14.3B $14.9B $13.9B